Canada Markets closed

Pfizer Inc. (PFE)

NYSE - NYSE Delayed Price. Currency in USD
Add to watchlist
54.33+0.96 (+1.80%)
At close: 04:02PM EST
54.62 +0.29 (+0.53%)
After hours: 07:58PM EST
Full screen
Trade prices are not sourced from all markets
Previous Close53.37
Open53.77
Bid54.51 x 1400
Ask54.60 x 2200
Day's Range53.10 - 54.67
52 Week Range33.36 - 61.71
Volume27,653,026
Avg. Volume45,653,990
Market Cap304.947B
Beta (5Y Monthly)0.62
PE Ratio (TTM)15.52
EPS (TTM)3.50
Earnings DateFeb. 08, 2022
Forward Dividend & Yield1.60 (2.93%)
Ex-Dividend DateJan. 27, 2022
1y Target EstN/A
  • Editor's Pick
    Yahoo Finance Video

    Omicron: Military medical team helping New Jersey amid coronavirus wave

    University Hospital CEO and former NJDOH Commissioner Dr. Shereef Elnahal joins Yahoo Finance Live to discuss how 25 military personnel are helping with staff shortages.

  • Editor's Pick
    Yahoo Finance Video

    Coronavirus: What to know about ‘stealth’ COVID variant hitting Europe, Asia

    BA.2 Omicron subvariant is appearing in Europe and Asia. Yahoo Finance's Anjalee Khemlani explains everything we know about this coronavirus strain so far.

  • Reuters

    COVID SCIENCE-Easier to produce COVID vaccine shows promise in trials; nasal spray vaccine booster works in mice

    A COVID-19 vaccine that can be produced locally in low- and middle-income countries is yielding promising results in early clinical trials, researchers say. The NDV-HXP-S vaccine, developed at Icahn School of Medicine at Mount Sinai in New York City, uses an engineered version of the harmless Newcastle disease virus studded with coronavirus spike proteins to teach the immune system to recognize and attack the virus that causes COVID. Using blood samples from trial participants, researchers found that NDV-HXP-S induces proportionally more antibodies that can neutralize the virus and fewer non-neutralizing antibodies than the current mRNA vaccines from Moderna or Pfizer/BioNTech, they reported on Friday on medRxiv https://www.medrxiv.org/content/10.1101/2022.01.25.22269808v1 ahead of peer review.